NHS: Drugs
Commons · Question 69242 · Tabled 21 Jul 2025 · Department of Health and Social Care · Official record
Answered 1 Sep 2025
Question
Asked by Jim Shannon
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of requiring NHS England to establish an agreement in principle with pharmaceutical companies that commercial flexibility may be granted for a
Answer
Answered by Karin Smyth, 1 Sep 2025
Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...